Sangart Garners $50,000,000 New Funding
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=6e870e93-7f7a-45cd-b783-c47d6c2be15b&Preview=1 -
Date
4/20/2011 -
Company Name
Sangart -
Mailing Address
6175 Lusk Blvd San Diego, CA 92121 -
Company Description
Sangart, Inc. is a biopharmaceutical company focused on the research, development and commercialization of oxygen transport agents. -
Website
http://www.sangart.com -
Transaction Type
Venture Equity -
Transaction Amount
$50,000,000 -
Transaction Round
Undisclosed -
Proceeds Purposes
This series G funding will allow us to continue advancing the development of our medicines and get them as quickly as possible to patients in need. We continue to see promise in our MP4-based medicines in the treatment of patients who experience an acute traumatic injury and in patients with sickle cell disease suffering from a vaso-occlusive crisis. -
M&A Terms
-
Venture Investor
Leucadia National Corp -
Venture Investor
Undisclosed
